Coronavirus Pandemic: Apocalypse Now! Or exaggerated scare story?

[Joan]

I came across this After Skool video this morning, It's Alan Watts, discussing The Road to Hell is paved with Good Intentions. I thought it was appropriate for our situation today.

 

[Woodsman]

James Corbett and the fellow who runs "Media Monarchy" (another blog channel) often join forces for weekly live conversation and note-comparing. They also do an annual year-end tie up of the various stories they've reported on over the previous 12 months, and make predictions for the next year.

Anyway, these images were brought up in their review of the Corona scare accompanied by their typically prescient remarks, concerning in this case, similarities between Gitmo torture and control circa 2013, and the imprisonment of a non-sick population today.

I thought they were worth a share here.











Watch the full video here:

 

[XPan]

James Corbett

is absolutely amazing. One of the sharpest minds on the internet when it comes to 3D realities with many multi-leveled agendas active under disguise.

To shed light into so many agendas being played out through lies, deceptions and pre programming...

Plus, that he does deep homework, always refers to sources and backs up everything he says and points at.

It makes my mind spin how he connects the dots, chisels out the fine important details and brings it all down to a level which makes complex deceptions and agendas better accessible to the reader/listener. And he encourages people to their own research as well.

A great resource

 

[Lucius]

Hi I don't have much time. Then if someone know what is google hacking with keyworlds site:[www.name.name] filetype:pdf;xlsx etc. you can find some good stuff about covid and vaccine Some of them I'm posting here (they can be deleted any second]

REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS

1
REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS
2
Version 4.0 24/12/2020
This medicinal product does not have a UK marketing authorisation but has been given
authorisation for temporary supply by the UK Department of Health and Social Care and the
Medicines & Healthcare products Regulatory Agency for active immunization to prevent
COVID-19 disease caused by SARS-CoV-2 virus in individuals aged 16 years of age and over.
As with any new medicine in the UK, this product will be closely monitored to allow quick
identification of new safety information. Healthcare professionals are asked to report any
suspected adverse reactions. See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
This is a multidose vial and must be diluted before use. 1 vial (0.45 mL) contains 5 doses of
30 micrograms of BNT162b2 RNA (embedded in lipid nanoparticles).
COVID-19 mRNA Vaccine BNT162b2 is highly purified single-stranded, 5’-capped messenger RNA
(mRNA) produced by cell-free in vitro transcription from the corresponding DNA templates, encoding
the viral spike (S) protein of SARS-CoV-2.
Excipients with known effect:
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Concentrate for solution for injection.
The vaccine is a white to off-white frozen solution.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of
age and older.
The use of COVID-19 mRNA Vaccine BNT162b2 should be in accordance with official guidance.
4.2 Posology and method of administration
Posology
Individuals 16 years of age and older
COVID-19 mRNA Vaccine BNT162b2 is administered intramuscularly after dilution as a series of
two doses (0.3 mL each) 21 days apart (see section 5.1).
There are no data available on the interchangeability of COVID-19 mRNA Vaccine BNT162b2 with
other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose
of COVID-19 mRNA Vaccine BNT162b2 should receive a second dose of COVID-19 mRNA
Vaccine BNT162b2 to complete the vaccination series.
Individuals may not be protected until at least 7 days after their second dose of the vaccine.
3
Version 4.0 24/12/2020
For further information on efficacy, see section 5.1.
Paediatric population
The safety and efficacy of COVID-19 mRNA Vaccine BNT162b2 in children under 16 years of age
have not yet been established.
Method of administration
Administer the COVID-19 mRNA Vaccine BNT162b2 vaccine intramuscularly in the deltoid muscle
after dilution.
Do not inject the vaccine intravascularly, subcutaneously or intradermally.
Preparation: The multidose vial is stored frozen and must be thawed prior to dilution.
Frozen vials should be transferred to 2 °C to
8 °C to thaw.
Alternatively, frozen vials may also be thawed
and kept at temperatures up to 25 °C for a
maximum of two hours in preparation for
dilution for use.
When removed from the freezer, the undiluted
vaccine has a maximum shelf life of up to
5 days (120 hours) at 2 °C to 8 °C and an
additional 2 hours at temperatures up to 25 °C in
preparation for dilution.
When the thawed vial is at room temperature
gently invert 10 times prior to dilution. Do not
shake. Prior to dilution the vaccine should
present as an off-white solution with no
particulates visible. Discard the vaccine if
particulates or discolouration are present.
The thawed vaccine must be diluted in its
original vial with 1.8 mL sodium chloride
9 mg/mL (0.9%) solution for injection, using a
21 gauge or narrower needle and aseptic
techniques.
Warning: Unpreserved sodium chloride
9 mg/mL (0.9%) solution for injection is the
only diluent that should be used. This diluent is
not provided in the vaccine carton.
4
Version 4.0 24/12/2020
Equalise vial pressure before removing the
needle from the vial by withdrawing 1.8 mL air
into the empty diluent syringe.
Gently invert the diluted solution 10 times. Do
not shake.
The diluted vaccine should present as an offwhite solution with no particulates visible.
Discard the diluted vaccine if particulates or
discolouration are present.
The diluted vials should be marked with the
dilution date and time and stored between 2 °C
to 25 °C.
Use as soon as practically possible, and within 6
hours after dilution.
5
Version 4.0 24/12/2020
After dilution, the vial contains 5 doses of
0.3 mL. Withdraw the required 0.3 mL dose of
diluted vaccine using a sterile needle and
syringe and administer. Vial volume was
optimized to reliably obtain 5 doses regardless
of syringe type used as most syringe and needle
combinations require withdrawal of excess
volume in order to ensure the full 0.3 mL dose
of vaccine can be administered. When low deadvolume syringes and/or needles are used, the
amount remaining in the vial after 5 doses have
been extracted may be sufficient for an
additional (sixth) dose. Care should be taken to
ensure a full 0.3 mL will be administered to the
subject and that all doses from a single prepared
vial are administered within 6 hours of the time
of dilution. Where a full 0.3 mL dose cannot be
extracted the contents should be discarded.
Any unused vaccine should be discarded
6 hours after dilution.
The vaccine should not be shipped (transported)
by motor vehicle after dilution away from the
site of dilution. Any shipping (transportation) by
motor vehicle after dilution of the vial is at the
risk of the Health Care Professional.
For instructions on disposal see section 6.6.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
Anaphylaxis
Any person with a history of immediate-onset anaphylaxis to a vaccine, medicine or food should not
receive the COVID-19 mRNA Vaccine BNT162b2. A second dose of the COVID-19 mRNA Vaccine
BNT162b2 should not be given to those who have experienced anaphylaxis to the first dose of
COVID-19 mRNA Vaccine BNT162b2.
As with all injectable vaccines, appropriate medical treatment and supervision should always be
readily available in case of a rare anaphylactic event following the administration of the vaccine.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number
of the administered product should be clearly recorded.
General recommendations
As with all injectable vaccines, appropriate medical treatment and supervision should always be
readily available in case of a rare anaphylactic event following the administration of the vaccine.
The administration of COVID-19 mRNA Vaccine BNT162b2 should be postponed in individuals
suffering from acute severe febrile illness.
6
Version 4.0 24/12/2020
Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate
intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs
the risk of administration.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have
a diminished immune response to the vaccine. No data are available about concomitant use of
immunosuppressants.
As with any vaccine, vaccination with COVID-19 mRNA Vaccine BNT162b2 may not protect all
vaccine recipients.
No data are available on the use of COVID-19 mRNA Vaccine BNT162b2 in persons that have
previously received a full or partial vaccine series with another COVID-19 vaccine.
Excipient information
This vaccine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially ‘potassium-free’.
This vaccine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium‑free’.
4.5 Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
Concomitant administration of COVID-19 mRNA Vaccine BNT162b2 with other vaccines has not
been studied (see section 5.1).
Do not mix COVID-19 mRNA Vaccine BNT162b2 with other vaccines/products in the same syringe.
4.6 Fertility, pregnancy and lactation
Pregnancy
There are no or limited amount of data from the use of COVID-19 mRNA Vaccine BNT162b2.
Animal reproductive toxicity studies have not been completed. COVID-19 mRNA Vaccine
BNT162b2 is not recommended during pregnancy.
For women of childbearing age, pregnancy should be excluded before vaccination. In addition, women
of childbearing age should be advised to avoid pregnancy for at least 2 months after their second dose.
Breast-feeding
It is unknown whether COVID-19 mRNA Vaccine BNT162b2 is excreted in human milk. A risk to
the newborns/infants cannot be excluded. COVID-19 mRNA Vaccine BNT162b2 should not be used
during breast-feeding.
Fertility
It is unknown whether COVID-19 mRNA Vaccine BNT162b2 has an impact on fertility.
4.7 Effects on ability to drive and use machines
COVID-19 mRNA Vaccine BNT162b2 has no or negligible influence on the ability to drive and use
machines. However, some of the adverse reactions mentioned under section 4.8 may temporarily
affect the ability to drive or use machines.
4.8 Undesirable effects
Summary of safety profile
The safety of COVID-19 mRNA Vaccine BNT162b2 was evaluated in participants 16 years of age
and older in two clinical studies conducted in the United States, Europe, Turkey, South Africa, and
7
Version 4.0 24/12/2020
South America. Study BNT162-01 (Study 1) enrolled 60 participants, 18 through 55 years of age.
Study C4591001 (Study 2) enrolled approximately 44,000 participants, 12 years of age or older.
In Study 2, a total of 21,720 participants 16 years of age or older received at least one dose of COVID19 mRNA Vaccine BNT162b and 21,728 participants 16 years of age or older received placebo. Out
of these, at the time of the analysis, 19,067 (9531 COVID-19 mRNA Vaccine BNT162b2 and
9536 placebo) were evaluated for safety 2 months after the second dose of COVID-19 mRNA Vaccine
BNT162b2.
Demographic characteristics were generally similar with regard to age, gender, race and ethnicity
among participants who received COVID-19 mRNA Vaccine and those who received placebo.
Overall, among the participants who received COVID-19 mRNA Vaccine BNT162b2, 51.5% were
male and 48.5% were female, 82.1% were White, 9.6% were Black or African American, 26.1% were
Hispanic/Latino, 4.3% were Asian and 0.7% were Native American/Alaskan native.
The most frequent adverse reactions in participants 16 years of age and older were pain at the injection
site (> 80%), fatigue (> 60%), headache (> 50%), myalgia (> 30%), chills (> 30%), arthralgia (> 20%)
and pyrexia (> 10%) and were usually mild or moderate in intensity and resolved within a few days
after vaccination. If required, symptomatic treatment with analgesic and/or anti-pyretic medicinal
products (e.g. paracetamol-containing products) may be used.
Adverse reactions from clinical studies
Adverse reactions reported in clinical studies are listed in this section per MedDRA system organ
class, in decreasing order of frequency and seriousness. The frequency is defined as follows: very
common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to
< 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from available data).
Blood and lymphatic system disorders
Uncommon: Lymphadenopathy
Nervous system disorders
Very common: Headache
Musculoskeletal and connective tissue disorders
Very common: Arthralgia; myalgia
General disorders and administration site conditions
Very common: Injection-site pain; fatigue; chills; pyrexia
Common: Redness at injection site; injection site swelling
Uncommon: Malaise
Gastrointestinal disorders
Common Nausea
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the Coronavirus Yellow Card
reporting site Homepage | Coronavirus (COVID-19)
or search for MHRA Yellow Card in the Google Play or Apple App Store
and include the vaccine brand and batch/Lot number if available.
4.9 Overdose
Participants who received 58 micrograms of COVID-19 mRNA Vaccine in clinical trials did not
report an increase in reactogenicity or adverse events.
8
Version 4.0 24/12/2020
In the event of overdose, monitoring of vital functions and possible symptomatic treatment is
recommended.
5. PHARMACODYNAMIC PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: {group}, ATC code: not yet assigned
Mechanism of action
The nucleoside-modified messenger RNA in COVID-19 mRNA Vaccine BNT162b2 is formulated in
lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARSCoV-2 S antigen. The vaccine elicits both neutralizing antibody and cellular immune responses to the
spike (S) antigen, which may contribute to protection against COVID-19 disease.
Efficacy in participants 16 years of age and older
The efficacy of COVID-19 mRNA Vaccine BNT162b2 was evaluated in participants 16 years of age
and older in two clinical studies conducted in the United States, Europe, Turkey, South Africa and
South America. Study 1 enrolled 60 participants, 18 through 55 years of age. Study 2 is a multicentre,
placebo-controlled efficacy study in participants 12 years of age and older. Randomisation was
stratified by age: 12 through 15 years of age, 16 through 55 years of age, or 56 years of age and older,
with a minimum of 40% of participants in the ≥ 56-year stratum. The study excluded participants who
were immunocompromised and those who had previous clinical or microbiological diagnosis of
COVID-19 disease. Participants with pre-existing stable disease, defined as disease not requiring
significant change in therapy or hospitalization for worsening disease during the 6 weeks before
enrolment, were included as were participants with known stable infection with human
immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV). There was no
requirement for prophylactic use of paracetamol or analgesics. Influenza vaccines could be
administered outside a window ± 14 days of the vaccine doses.
In Study 2, approximately 44,000 participants 12 years of age and older were randomised equally and
received 2 doses of COVID-19 mRNA Vaccine or placebo with a planned interval of 21 days. The
efficacy analyses included participants that received their second vaccination within 19 to 42 days
after their first vaccination. Participants are planned to be followed for up to 24 months, for
assessments of safety and efficacy against COVID-19 disease.
The population for the analysis of the primary efficacy endpoint included, 36,621 participants 12 years
of age and older (18,242 in the COVID-19 mRNA Vaccine group and 18,379 in the placebo group)
who did not have evidence of prior infection with SARS-CoV-2 through 7 days after the second dose.
Demographic characteristics were generally similar with regard to age, gender, race and ethnicity
among participants who received COVID-19 mRNA BNT162b2 vaccine and those who received
placebo. Overall, among the participants who received COVID-19 mRNA vaccine, 51.1% were male
and 48.9% were female, 82.8% were White, 8.9% were Black or African American, 26.8% were
Hispanic/Latino, 4.5% were Asian and 0.6% were Native American/Alaskan native. 57.2% were aged
16-55 years, 42.6% were aged > 55 years and 21.8% were ≥ 65 years.
Efficacy against COVID-19 disease
At the time of the analysis of Study 2, information presented is based on participants 16 years and
older. Participants had been followed for symptomatic COVID-19 disease for at least 2,214
person-years for the COVID-19 mRNA Vaccine and at least 2,222 person-years in the placebo group.
There were 8 confirmed COVID-19 cases identified in the COVID-19 mRNA Vaccine group and 162
cases in the placebo group, respectively. In this analysis, compared to placebo, efficacy of COVID-19
mRNA Vaccine BNT162b2 from first COVID-19 occurrence from 7 days after Dose 2 in participants
without evidence of prior infection with SARS-CoV-2 was 95.0% (95% credible interval of 90.3% to
9
Version 4.0 24/12/2020
97.6%). In participants 65 years of age and older and 75 years of age and older without evidence of
prior infections with SARS-CoV-2, efficacy of COVID-19 mRNA Vaccine BNT162b2 was 94.7%
(two-sided 95% confidence interval of 66.7% to 99.9%) and 100% (two-sided 95% confidence
interval of -13.1% to 100.0%) respectively.
In a separate analysis, compared to placebo, efficacy of COVID-19 mRNA Vaccine from first
COVID-19 occurrence from 7 days after Dose 2 in participants with or without evidence of prior
infection with SARS-CoV-2 was 94.6% (95% credible interval of 89.9% to 97.3%).
There were no meaningful clinical differences in overall vaccine efficacy in participants who were at
risk of severe COVID-19 disease including those with one or more comorbidities that increase the risk
of severe COVID-19 disease (e.g. asthma, BMI ≥ 30 kg/m2
, chronic pulmonary disease, diabetes
mellitus, hypertension).
Confirmed cases were determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
and at least 1 symptom consistent with COVID-19 disease*.
*Case definition (at least 1 of): fever, new or increased cough, new or increased shortness of breath;
chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhoea or vomiting.
5.2 Pharmacokinetic properties
Not applicable.
5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on a conventional study of repeat dose
toxicity. Animal studies into potential toxicity to reproduction and development have not been
completed.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
This vaccine contains polyethylene glycol/macrogol (PEG) as part of ALC-0159.
ALC-0315 = (4-hydroxybutyl) azanediyl)bis (hexane-6,1-diyl)bis(2-hexyldecanoate),
ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide,
1,2-Distearoyl-sn-glycero-3-phosphocholine,
cholesterol,
potassium chloride,
potassium dihydrogen phosphate,
sodium chloride,
disodium hydrogen phosphate dihydrate,
sucrose,
water for injections
6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal
products.
6.3 Shelf life
6 months at -80 °C to -60 °C.
10
Version 4.0 24/12/2020
6.4 Special precautions for storage
Store in a freezer at -80 °C to -60 °C.
Store in the thermal container at -90 ºC to -60 ºC.
Store in the original package in order to protect from light.
Once removed from the freezer, the undiluted vaccine can be stored for up to 5 days at 2 °C to 8 °C,
and up to 2 hours at temperatures up to 25 °C, prior to use. During storage, minimise exposure to room
light, and avoid exposure to direct sunlight and ultraviolet light. Thawed vials can be handled in room
light conditions.
After dilution, store the vaccine at 2 °C to 25 °C and use as soon as practically possible and within
6 hours. The vaccine does not contain a preservative. Discard any unused vaccine.
Once diluted, the vials should be marked with the dilution time and discarded within 6 hours of
dilution.
Once thawed, the vaccine cannot be re-frozen.
6.5 Nature and contents of container
Concentrate for solution for injection for 5 doses in a 2 mL clear vial (type I glass) with a stopper
(bromobutyl) and a flip-off plastic cap with aluminium seal.
Pack size: 195 vials
6.6 Special precautions for disposal and other handling
When removed from the freezer, the vaccine has a maximum possible shelf life of up to 5 days when
stored at 2-8 ºC (label to be added once box removed from freezer). A 195 vial pack may take 3 hours
to thaw at 2-8
oC.
The product can alternatively be defrosted and kept for up to 2 hours at up to 25 ºC before being
diluted for use. This facilitates immediate thaw and use when removed directly from the freezer to
25 ºC. In this instance the product is to be diluted within 2 hours of removing from the freezer.
Once thawed, the vaccine cannot be refrozen.
After dilution the vaccine should be used as soon as is practically possible and within 6 hours of
dilution; it can be stored at 2-25 ºC during this period. From a microbiological point of view, it would
not normally be considered good practice to store a diluted product for 6 hours at 25 ºC before being
administered. The product would ideally be used as soon as practically possible after dilution.
The vaccine does not contain a preservative. Discard any unused vaccine.
Any unused medicinal product or waste material should be disposed of in accordance with local
requirements.
For instructions on dose preparation of the medicinal product before administration, see section 4.2.
7. MARKETING AUTHORISATION HOLDER
Not applicable.
11
Version 4.0 24/12/2020
8. MARKETING AUTHORISATION NUMBER(S)
Not applicable.
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Not applicable.
10. DATE OF REVISION OF THE TEXT
December 2020

There are some stuff from usa florida gov site: stats

Filelist - poor security Florida - vaccine plane, stats per day etc.
vaccine_report_latest FL

and deathsIndex of /comm/_partners/covid19_report_archive/correction-facilities-deaths

	Name	Last modified	Size	Description
	Parent Directory		-​
	fdc_death_20200506.pdf	30-Jun-2020 16:00​	194K​
	fdc_death_20200513.pdf	30-Jun-2020 16:00​	122K​
	fdc_death_20200520.pdf	30-Jun-2020 16:01​	88K​
	fdc_death_20200527.pdf	30-Jun-2020 16:01​	90K​
	fdc_death_20200603.pdf	30-Jun-2020 16:01​	123K​
	fdc_death_20200610.pdf	30-Jun-2020 16:01​	123K​
	fdc_death_20200617.pdf	30-Jun-2020 16:01​	123K​
	fdc_death_20200624.pdf	30-Jun-2020 16:01​	123K​
	fdc_death_20200701.pdf	01-Jul-2020 16:17​	123K​
	fdc_death_20200708.pdf	08-Jul-2020 11:50​	123K​
	fdc_death_20200715.pdf	16-Jul-2020 10:32​	123K​
	fdc_death_20200722.pdf	22-Jul-2020 14:00​	123K​
	fdc_death_20200729.pdf	29-Jul-2020 10:53​	124K​
	fdc_death_20200805.pdf	05-Aug-2020 14:23​	124K​
	fdc_death_20200812.pdf	13-Aug-2020 08:14​	125K​
	fdc_death_20200812_archived.pdf	12-Aug-2020 12:23​	124K​
	fdc_death_20200819.pdf	20-Aug-2020 10:04​	124K​
	fdc_death_20200826.pdf	28-Aug-2020 11:27​	124K​
	fdc_death_20200903.pdf	26-Aug-2020 16:50​	97K​
	fdc_death_20200909.pdf	09-Sep-2020 12:23​	125K​
	fdc_death_20200916.pdf	09-Sep-2020 12:23​	125K​
	fdc_death_20200923.pdf	23-Sep-2020 15:12​	137K​
	fdc_death_20200930.pdf	23-Sep-2020 15:12​	137K​
	fdc_death_20201007.pdf	07-Oct-2020 15:18​	125K​
	fdc_death_20201014.pdf	07-Oct-2020 15:18​	125K​
	fdc_death_20201021.pdf	21-Oct-2020 11:14​	125K​
	fdc_death_20201028.pdf	21-Oct-2020 11:14​	125K​
	fdc_death_20201104.pdf	28-Oct-2020 11:31​	124K​
	fdc_death_20201112.pdf	04-Nov-2020 10:09​	125K​
	fdc_death_20201118.pdf	12-Nov-2020 16:00​	124K​
	fdc_death_20201125.pdf	18-Nov-2020 10:54​	124K​
	fdc_death_20201202.pdf	25-Nov-2020 11:04​	124K​
	fdc_death_20201209.pdf	02-Dec-2020 15:39​	133K​
	fdc_death_20201223.pdf	09-Dec-2020 10:59​	124K​
	fdc_death_latest.pdf	23-Dec-2020 10:55​	124K​

Index of /comm/_partners/covid19_report_archive/cases-monitoring-and-pui-information​

	Name	Last modified	Size	Description
	Parent Directory		-​
	county-report/	24-Dec-2020 15:12​	-​
	state-linelist/	24-Dec-2020 14:56​	-​
	state-report/	24-Dec-2020 15:14​	-​

Apache/2.2.15 (CentOS) Server at ww11.doh.state.fl.us Port 80

	Parent Directory		-​
	vaccine_report_20201220.pdf	19-Dec-2020 11:37​	133K​
	vaccine_report_20201221.pdf	20-Dec-2020 15:23​	133K​
	vaccine_report_20201222.pdf	21-Dec-2020 15:17​	129K​
	vaccine_report_20201223.pdf	22-Dec-2020 14:19​	136K​
	vaccine_report_20201224.pdf	23-Dec-2020 11:48​	137K​
	vaccine_report_latest.pdf	24-Dec-2020 14:47​	138K​

Apache/2.2.15 (CentOS) Server at ww11.doh.state.fl.us Port 80

Index of /comm/_partners/covid19_report_archive/vaccination-plan​

	Name	Last modified	Size	Description
	Parent Directory		-​
	vaccination_plan_20201023.pdf	23-Oct-2020 17:04​	1.2M​
	vaccination_plan_latest.pdf	23-Oct-2020 17:04​	1.2M​

Apache/2.2.15 (CentOS) Server at ww11.doh.state.fl.us Port 80

	aaa_[report_name]_YYYYMMDD_hhmm.txt	11-Jul-2020 12:33​	0​
	cases-monitoring-and-pui-information/	30-Sep-2020 17:50​	-​
	cases-of-residents-over-the-age-65/	30-Sep-2020 17:55​	-​
	correction-facilities-deaths/	23-Dec-2020 10:58​	-​
	licensed-group-homes-cases/	04-Dec-2020 11:48​	-​
	long-term-care-facilities/	30-Sep-2020 19:52​	-​
	pediatric-reports/	24-Dec-2020 15:17​	-​
	school-reports/	23-Dec-2020 08:04​	-​
	total-antibody-results/	01-Oct-2020 14:57​	-​
	vaccination-plan/	23-Oct-2020 17:04​	-​
	vaccine/	24-Dec-2020 15:18​	-​

Apache/2.2.15 (CentOS) Server at ww11.doh.state.fl.us Port 80

 

[Lucius]

And pdf that was online only for 2 days - deleted from site but google webcache still has IT:

Product Information as approved by the CHMP on 21 December 2020, pendingendorsement by the European Commission

 

[Lucius]

If you have time to read:

Research Paper Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV2: A preliminary report of an open-label, Phase 1 clinical trial

Research in context
Evidence before this study
INO-4800 is among several vaccines being tested against SARSCoV-2, the virus that causes COVID-19 disease with the goal of
inducing a protective immune response. The DNA vaccine, INO4800, delivered intradermally with CELLECTRA electroporation (EP) delivery system, induces a balanced immune response
that includes engagement of both T cells and B cells [15].
Added value of this study
This is the first report of a clinical trial of INO-4800, a DNA vaccine targeting the SARS-CoV-2 spike antigen delivered by the
ID route by CELLECTRA EP. The vaccine was safe and well tolerated with only Grade 1 AEs observed, and without increased
AEs post dose two. Two doses of INO-4800, delivered by the ID
route by CELLECTRA EP leads to an increased immune response
without added reactogenicity. All volunteers mounted an antispike immune response following the second dose of the
vaccine.
Implications of all the available evidence
The safety profile for INO-4800 is important as there were just 6
vaccine-related Grade 1 events in 5 subjects. In addition these
were distributed similarly between the two dose groups, supporting the tolerability of this vaccine across dose groups.
Therefore, INO-48000
s ability to induce broad immune
responses as well as favorable tolerability and product temperature stability position this vaccine attractive especially for
lower/middle income countries. Finally, the safety and tolerability profile appears supportive for expanded study in diverse
individuals and those where inflammatory responses may be a
concern. A study in populations 51 years old and older is now
in progress (NCT04336410. ClinicalTrials.gov).

ABSTRACT Background: A vaccine against SARS-CoV-2 is of high urgency. Here the safety and immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of SARS-CoV-2 are described. Methods: INO-4800 was evaluated in two groups of 20 participants, receiving either 1.0 mg or 2.0 mg of vaccine intradermally followed by CELLECTRA EP at 0 and 4 weeks. Thirty-nine subjects completed both doses; one subject in the 2.0 mg group discontinued trial participation prior to receiving the second dose. ClinicalTrials.gov identifier: NCT04336410. Findings: The median age was 34.5, 55% (22/40) were men and 82.5% (33/40) white. Through week 8, only 6 related Grade 1 adverse events in 5 subjects were observed. None of these increased in frequency with the second administration. No serious adverse events were reported. All 38 subjects evaluable for immunogenicity had cellular and/or humoral immune responses following the second dose of INO-4800. By week 6, 95% (36/38) of the participants seroconverted based on their responses by generating binding (ELISA) and/or neutralizing antibodies (PRNT IC50), with responder geometric mean binding antibody titers of 655.5 [95% CI (255.6, 1681.0)] and 994.2 [95% CI (395.3, 2500.3)] in the 1.0 mg and 2.0 mg groups, respectively. For neutralizing antibody, 78% (14/18) and 84% (16/19) generated a response with corresponding geometric mean titers of 102.3 [95% CI (37.4, 280.3)] and 63.5 [95% CI (39.6, 101.8)], in the respective groups. By week 8, 74% (14/ 19) and 100% (19/19) of subjects generated T cell responses by IFN-ɣ ELISpot assay with the median SFU per 106 PBMC of 46 [95% CI (21.1, 142.2)] and 71 [95% CI (32.2, 194.4)] in the 1.0 mg and 2.0 mg groups, respectively. Flow cytometry demonstrated a T cell response, dominated by CD8+ T cells co-producing IFN-ɣ and TNF-a, without increase in IL-4. Interpretation: INO-4800 demonstrated excellent safety and tolerability and was immunogenic in 100% (38/ 38) of the vaccinated subjects by eliciting either or both humoral or cellular immune responses. Funding: Coalition for Epidemic Preparedness Innovations (CEPI). Crown Copyright © 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (Creative Commons — Attribution-NonCommercial-NoDerivatives 4.0 International — CC BY-NC-ND 4.0)

 

[Nucifera]

Comprehensive analysis of 50 states shows greater spread with mask mandates​

I can't vouch for the stats or methodology, but the results appear to show that mask mandates raise the case rates. [The problem being the definition of "case." That's a big can of worms with a load of questionable science. Still, I thought it interesting enough to share.]

The results: When comparing states with mandates vs. those without, or periods of times within a state with a mandate vs. without, there is absolutely no evidence the mask mandate worked to slow the spread one iota. In total, in the states that had a mandate in effect, there were 9,605,256 confirmed COVID cases over 5,907 total days, an average of 27 cases per 100,000 per day. When states did not have a statewide order (which includes the states that never had them and the period of time masking states did not have the mandate in place) there were 5,781,716 cases over 5,772 total days, averaging 17 cases per 100,000 people per day.

Horowitz: Comprehensive analysis of 50 states shows greater spread with mask mandates | Blaze Media

How long do our politicians get to ignore the results?

www.theblaze.com

 

[XPan]

Comprehensive analysis of 50 states shows greater spread with mask mandates​

I can't vouch for the stats or methodology, but the results appear to show that mask mandates raise the case rates. [The problem being the definition of "case." That's a big can of worms with a load of questionable science. Still, I thought it interesting enough to share.]

Horowitz: Comprehensive analysis of 50 states shows greater spread with mask mandates | Blaze Media

How long do our politicians get to ignore the results?

www.theblaze.com

Of course it does !

(I mean, I am not really surprised)

After reading articles and listening to medical people who study these things very closely, writing about the backside of masks - you start to realize that it sets a deeper footprint onto those fraudulent PCR tests - with even more "positive" cases. PCR cross-reacts to all kinds of genetic material, especially everything above 25 cycles.

You produce more particles (viral, bacterial, fungal) under an unhealthy environment like wearing a moist mask for long times. Also pneumonia cases rise because of that.

There is a significant decrease of oxygen under a mask - and a really high rise of CO2 back breathing. The latter is directly dangerous for children, especially in the empty / undeveloped parts of their lungs, with levels up to 45.000 ppm have been measured in a study recently done in Bolzano, Italy - leading to very fast acidosis in the local lung tissue.

It is beyond irresponsible to make children wear masks.

I have no words !

 

[XPan]

If you have time to read:

Research Paper Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV2: A preliminary report of an open-label, Phase 1 clinical trial

INO-4800 Vaccine Candidate

So, this "vaccine" is of DNA type (not mRNA). Does that mean, it interacts directly with our cell DNA ? Damages of any kind would be multiplied for each new cell ?

 

[XPan]

INO-4800 Vaccine Candidate

So, this "vaccine" is of DNA type (not mRNA). Does that mean, it interacts directly with our cell DNA ? Damages of any kind would be multiplied for each new cell ?

Oh... The Paper states under "Funding" - "CEPI; Coalition for Epidemic Preparedness Innovations".

CEPI
Motto: 'New vaccines for a safer world'
Founders: Wellcome Trust, Bill & Melinda Gates Foundation, Germany, India, Japan, Norway, World Economic Forum

Our 'philanthropists' at work

How quaint.

 

[dredger]

Hello all,

There's something I feel strong on this, can't explain much why. I post this here but it could also be posted in the US election as it concerns the same.

There's a former French journalist who just posted a wonderful article adressed to journalists. First for the french ones but this is what is strong with this text, it's that it's adapted to any journalist in any country worldwide.
The author was really well inspired in this text, I categorize this article as a masterpiece in the actual context. And it's not so long.

Lettre ouverte aux journalistes de France et d’ailleurs | FranceSoir

Tribune NDLR : FranceSoir publie des articles rédigés par des journalistes mais également des contributions libres sous forme de tribune d'opinion ; ces dernières reflètent et engagent la position personnelle de leur auteur et non de celle de la rédaction de FranceSoir. Cette liberté...

www.francesoir.fr

So impressed that I traduced it (using deepl) and reformated it in order to have the article "printable" on 2 pages (or one page recto-verso) - I also added a small comment on top, an idea that crossed my head when doing the document ... ...
The PDF and RTF (editable) version are attached (EDIT : i dont know why by the .rtf file can't be attached, so there's only the PDF attached)
I'm going to send some copies of it in a near future . If any wish, I can recreate the same document in french, even if we can print from the website, it may be printed on too many pages - idea was to have it concentrated on 1 page r/v.

About sott.net, this article could be (traduced &) posted on all sites.
On twitter, I already read a first "counter-argument" (which in fact is not one, but it's a rather previsible one) : "I stopped reading when he writes about pedo-satanist" ...


I would say that here ... there's here a strong SDA influence. My first idea was : a christmas present for all mankind ... don't laugh, this was my very first impression, even before I terminated to read the article.
Having discussed with so many different type of (still) blinded people, this text should shake them strongly. Even if it's adressed to journalists, this article is, to my mind, adressed to any, just more particularly to the journalists ... as the author is a former one.

I also had thought about .... that if this article is well spread, I mean worldwide, we then could bet that a majority of journalists (worldwide) will read it ... and that this could lead to some perturbations in the mainstream medias .
Maybe more "mouths opening" on TV, some strikes, protests, testimonies, resignations, and certainly some scandals - it's Season 2 of the show which starts in January Fact is that I had such idea in the air since some months, regarding the people working in the mass media, not only the pure journalists, there are many technicians, IT, and all the various departements you can find in any company.

Spoiler: Script to the univers :

As we all participate to this show, I sent my own version of a script that I would be glad to see in the future, I hope it'll be retained.
Here's its description
In an important country, in a well known TV company, a great % of the staff silently organized themselves. They prepare a plan to take the control of the TV during a maximum of time, knowing they'll be stopped probably by the police after a while. During the time they'll be in measure to broadcast they would unfold all the lies they were oblige to say, all the information they were obliged to dismiss, all the pression they have, etc ... The country's local PTB rapidly reacts, but it's too late, video is already everywhere on the internet and some TV companies start to experience problems. Mass media are seriously hit, PTB must stop this, but how to ? That will be for the next season

 

[Ruth]

I think of the poor truckers...

And everything they're carrying? It's kind of like a siege mentality where the population of UK, France and even the world is being held hostage for "the good" of everyone else. It's really nothing more than an excuse in the end. For some people it's the perfect excuse.

 

[Mikkael]

Once again WHO is continuing in its practices, rewriting and changing meanings of the words to suit their agendas, previously re: pandemic and now their newest change is herd immunity concept.

This is original concept which was stated on their site in summer:


and now they have changed it and tied to vaccination:

ZeroHedge

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

www.zerohedge.com

 

[XPan]

There's a former French journalist who just posted a wonderful article adressed to journalists. First for the french ones but this is what is strong with this text, it's that it's adapted to any journalist in any country worldwide.
The author was really well inspired in this text, I categorize this article as a masterpiece in the actual context. And it's not so long.

Lettre ouverte aux journalistes de France et d’ailleurs | FranceSoir

Tribune NDLR : FranceSoir publie des articles rédigés par des journalistes mais également des contributions libres sous forme de tribune d'opinion ; ces dernières reflètent et engagent la position personnelle de leur auteur et non de celle de la rédaction de FranceSoir. Cette liberté...

www.francesoir.fr

That was a good text, direct on the spot.

I could imagine that in it's original french version - being even more powerful when read by the reporter colleagues. Since I do not speak french, I have to rely on my feeling/impressions from the french language; that it has an inherent strength "built in" which can be felt - the kind of "glue" that connects people, making them listen and reflect (not necessarily agree).

But stirring the waters of the journalists who gradually slid into the opposite of what they once thought they were doing (right) in their profession.

 

[XPan]

Once again WHO is continuing in its practices, rewriting and changing meanings of the words to suit their agendas, previously re: pandemic and now their newest change is herd immunity concept.

This is original concept which was stated on their site in summer:
View attachment 41031

and now they have changed it and tied to vaccination:

View attachment 41032

ZeroHedge

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

www.zerohedge.com

I just read this in Swedish

an half hour ago via Lars Bern's homepage "Anthropocene" that the WHO changed the definition of heard immunity - which in essence has become the direct opposite (subversion) of what herd immunity really is - e.g. training the immune system by exposing yourself to the viral/bacterial flora constantly, which gives you stronger protection (the immune system easily recognizes the critter viruses that repeatedly come along)

Like for example Grandparents which are often in contact with children, usually have a very good herd immunity for many viruses. But those who are isolated - get weaker protection as their immune system starts to "forget" - and can get more serious infections.

Interesting how the WHO is constantly double playing (giving opposite messages) of "good" and "bad".